Variant allele frequency as a predictor of treatment response to osimertinib in EGFR-mutated NSCLC

BackgroundOsimertinib has been approved as a treatment option for epidermal growth factor receptor (EGFR) mutated non-small cell lung cancer (NSCLC). However, despite the identification of common mutations, there are still no additional pathological factors that can be used to predict treatment resp...

Descrizione completa

Dettagli Bibliografici

Autori principali:	Walid Shalata, Bilal Krayim, Asmah Miari, Abed Agbarya, Nir Peled, Yulia Dudnik, Ahron Yehonatan Cohen, Amichay Meirovitz, Natalie Maimon Rabinovich, Alexander Yakobson, Firas Abu Akar, Ronen Brenner
Natura:	Artigo
Lingua:	Inglês
Pubblicazione:	Frontiers Media S.A. 2026-04-01
Serie:	Frontiers in Molecular Biosciences
Soggetti:	EGFR non-small cell lung cancer osimertinib overall survival progression-free survival variant allele frequency
Accesso online:	https://www.frontiersin.org/articles/10.3389/fmolb.2026.1822285/full
Tags:	Aggiungi Tag Nessun Tag, puoi essere il primo ad aggiungerne!!